GILD34:BVMF
Gilead Sciences Inc BDR
R$ 65.69
arrow_downward
-0.18%(-0.12) 1D
10-р сарын 19, 10:25:17 (GMT-3) · BRL
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GILD34...
Open
R$ 65.69
High
R$ 65.69
Low
R$ 65.69
Mkt. cap
191.67Т
Avg. vol.
319.00
Volume
1.00
52-wk high
R$ 67.38
52-wk low
R$ 51.33
Shares outstanding
1.24 тэрбум
No. of employees
17 мян
Open
R$ 65.69
High
R$ 65.69
Low
R$ 65.69
Mkt. cap
191.67Т
Avg. vol.
319.00
Volume
1.00
52-wk high
R$ 67.38
52-wk low
R$ 51.33
Shares outstanding
1.24 тэрбум
No. of employees
17 мян
News stories
From web sources and news partners
Trefis
·
16 минутын өмнө
What Has Changed About Owning Gilead Stock?
ad-hoc-news.de
·
1 цагийн өмнө
Gilead Sciences stock: BofA lifts target for Gilead Sciences stock to USD 164.00
STAT
·
2 цагийн өмнө
Pharmalittle: We're reading about Roche investments in Germany, a Gilead bowel disease drug, and more
Investing.com
·
3 цагийн өмнө
Gilead to present HIV and antiviral research at IDWeek 2026
Profile
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade.
In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100.
The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia
About Gilead Sciences Inc BDR
CEODaniel O'Day
Employees17 мян
Founded1987 оны 6-р сарын 22
HeadquartersFoster City, Калифорни, Америкийн Нэгдсэн Улс
Sector-
Websitegilead.com